Engineering Microencapsulated Probiotics for Enhanced Aflatoxin M1 Mitigation in Milk
Probiotics and Antimicrobial Proteins · 16.11.2026
DOI: 10.1007/s12602-026-11248-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Probiotics and Antimicrobial Proteins, online erschienen am 16.11.2026. Verfasst von Marwa E A Kholeaf und 4 weiteren Autor:innen. Beteiligte Einrichtung: Reference Lab for Safety Analysis of Food of Animal Origin, Animal Health Research Institute (AHRI), Agricultural Research Center (ARC), Dokki, Egypt. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agricultural Research Center.
Abstract (Originalsprache)
Aflatoxin M 1 is a major mycotoxin found primarily in milk and dairy products that causes a severe public health risk to dairy product safety and the dairy industry. Therefore, the present study explored the effectiveness of micro-encapsulated Lactobacillus acidophilus , Lactobacillus Casei and Bifidobacterium bifidum in reducing AFM 1 in milk as promising and emerging strategies for eliminating and controlling AFM1 in milk. Nonetheless, it is challenging to maintain a high number of live cells in probiotic foods during storage and gastrointestinal transit. Microencapsulation of probiotic bacteria is an efficient approach to increase probiotic viability by minimizing cell exposure to harsh environments via the gastrointestinal tract before releasing them into the colon. Hence, Lactobacillus Casei , Lactobacillus acidophilus and Bifidobacterium bifidum were encapsulated with ionic gelation techniques in alginate/inulin microcapsules (LC/AL/IN), (LA/AL/IN), and (BB/AL/IN), with encapsulation yields of 87.5 ± 0.50%, 90.3 ± 0.71%, and 83.2 ± 0.33%, respectively. The morphology of the microcapsules was investigated with a scanning electron microscope. The encapsulation yield, particle size, zeta potential, and FTIR were investigated for the prepared microcapsule. The effect of (LC/AL/IN), (LA/AL/IN), and BB/AL/IN alone and their combined mixture was tested for mitigation of aflatoxin M1 in artificially contaminated milk with a reduction percentage of 91%, 91%, 76%, and 95.66%, respectively. These findings suggested that microencapsulated probiotics represent a safe and effective strategy for AFM1 management with a strong ability to decrease AFM1 in milk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Reference Lab for Safety Analysis of Food of Animal Origin, Animal Health Research Institute (AHRI), Agricultural Research Center (ARC), Dokki, Egypt.
- Nanomedicine Laboratories, Center for Materials Science (CMS), Zewail City of Science and Technology, Giza, Egypt.
- Pharmaceutical Chemistry Department, Egyptian Drug Authority (EDA, formerly National Organization for Drug Control and Research, NODCAR), Giza, Egypt.
- Reference Lab for Safety Analysis of Food of Animal Origin, Animal Health Research Institute (AHRI), Agricultural Research Center (ARC), Dokki, Egypt. shaymaa_vet2010@yahoo.com.
- NCNS, Academy of Scientific Research and Technology, Cairo, Egypt. shaymaa_vet2010@yahoo.com.
Förderung
- Agricultural Research Center
Zitieren
APA
Kholeaf, M. E. A., Dena, A. S. A., Hassan, A. E., Elokle, A. A., & Khalid, S. A. (2026). Engineering Microencapsulated Probiotics for Enhanced Aflatoxin M1 Mitigation in Milk. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-026-11248-8
Vancouver
Kholeaf MEA, Dena ASA, Hassan AE, Elokle AA, Khalid SA. Engineering Microencapsulated Probiotics for Enhanced Aflatoxin M1 Mitigation in Milk. Probiotics and Antimicrobial Proteins. 2026. doi:10.1007/s12602-026-11248-8
BibTeX
@article{Kholeaf2026,
author = {Kholeaf, Marwa E A and Dena, Ahmed S Abo and Hassan, Asmaa E and Elokle, Amira A and Khalid, Shaimaa A},
title = {Engineering Microencapsulated Probiotics for Enhanced Aflatoxin M1 Mitigation in Milk},
journal = {Probiotics and Antimicrobial Proteins},
year = {2026},
doi = {10.1007/s12602-026-11248-8}
}
EUVIMED